<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01940146</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_13_10</org_study_id>
    <nct_id>NCT01940146</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis</brief_title>
  <official_title>Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Advanced Research Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Advanced Research Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the efficacy and safety of SPARC1310 when compared to placebo and
      active control
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Nasal Symptom Score From Baseline to Day 14.</measure>
    <time_frame>Baseline to Day 14</time_frame>
    <description>The 4-point (0=None, 1=Mild, 2=Moderate, and 3=Severe) intensity scale was summed across multiple symptoms (nasal congestion, rhinorrhea, nasal itching, and sneezing). Thus, the TNSS scores could range from 0 to 12, with higher scores indicative of greater severity.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">222</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>SPARC Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SPARC1310 I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SPARC1310 II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SPARC1310 III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>SPARC Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC1310 I</intervention_name>
    <description>SPARC1310 I</description>
    <arm_group_label>SPARC1310 I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC1310 II</intervention_name>
    <description>SPARC1310 II</description>
    <arm_group_label>SPARC1310 II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC1310 III</intervention_name>
    <description>SPARC1310 III</description>
    <arm_group_label>SPARC1310 III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female participants aged 18 to 65 years with history of seasonal allergic
             rhinitis

          -  Participants able to understand and willing to sign the informed consent form

        Exclusion Criteria:

          -  Anotomical deviations of the nasal septum that significantly impair ventilation or
             airflow

          -  Pregnant or nursing women

          -  Positive serology for infectious disease (Hepatitis B or C, HIV) at screening

          -  Parallel participation in another current investigational study, participation in a
             study within less than 30 days prior to study entry, or previous participation in this
             same study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shravanti Bhowmik, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sun Pharma Advanced Research Company Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SPARC Site 1</name>
      <address>
        <city>Kingston</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2013</study_first_submitted>
  <study_first_submitted_qc>September 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2013</study_first_posted>
  <results_first_submitted>November 19, 2015</results_first_submitted>
  <results_first_submitted_qc>March 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 11, 2016</results_first_posted>
  <last_update_submitted>March 10, 2016</last_update_submitted>
  <last_update_submitted_qc>March 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SPARC Placebo</title>
          <description>SPARC Placebo was administered as sprays/nostril QD</description>
        </group>
        <group group_id="P2">
          <title>SPARC1310 I</title>
          <description>SPARC1310 I was administered as two sprays /nostril QD</description>
        </group>
        <group group_id="P3">
          <title>SPARC1310 II</title>
          <description>SPARC1310 II was administered as two sprays/nostril QD</description>
        </group>
        <group group_id="P4">
          <title>SPARC1310 III</title>
          <description>SPARC1310 III was administered as two sprays/nostril QD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="56"/>
                <participants group_id="P4" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SPARC Placebo</title>
          <description>Baseline characteristics: Age</description>
        </group>
        <group group_id="B2">
          <title>SPARC1310 I</title>
          <description>Baseline characteristics: Age</description>
        </group>
        <group group_id="B3">
          <title>SPARC1310 II</title>
          <description>S0597 mid dose: S0597 mid dose</description>
        </group>
        <group group_id="B4">
          <title>SPARC1310 III</title>
          <description>S0597 high dose: S0597 high dose</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="56"/>
            <count group_id="B4" value="55"/>
            <count group_id="B5" value="222"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="10.8"/>
                    <measurement group_id="B2" value="39" spread="9.5"/>
                    <measurement group_id="B3" value="39" spread="10.9"/>
                    <measurement group_id="B4" value="38" spread="10.6"/>
                    <measurement group_id="B5" value="39" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="18" upper_limit="63"/>
                    <measurement group_id="B2" value="36" lower_limit="24" upper_limit="59"/>
                    <measurement group_id="B3" value="38" lower_limit="19" upper_limit="63"/>
                    <measurement group_id="B4" value="37" lower_limit="19" upper_limit="65"/>
                    <measurement group_id="B5" value="37" lower_limit="18" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Nasal Symptom Score From Baseline to Day 14.</title>
        <description>The 4-point (0=None, 1=Mild, 2=Moderate, and 3=Severe) intensity scale was summed across multiple symptoms (nasal congestion, rhinorrhea, nasal itching, and sneezing). Thus, the TNSS scores could range from 0 to 12, with higher scores indicative of greater severity.</description>
        <time_frame>Baseline to Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>S0597 Low Dose</title>
            <description>S0597 low dose: S0597 low dose</description>
          </group>
          <group group_id="O3">
            <title>S0597 Mid Dose</title>
            <description>S0597 mid dose: S0597 mid dose</description>
          </group>
          <group group_id="O4">
            <title>S0597 High Dose</title>
            <description>S0597 high dose: S0597 high dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Nasal Symptom Score From Baseline to Day 14.</title>
          <description>The 4-point (0=None, 1=Mild, 2=Moderate, and 3=Severe) intensity scale was summed across multiple symptoms (nasal congestion, rhinorrhea, nasal itching, and sneezing). Thus, the TNSS scores could range from 0 to 12, with higher scores indicative of greater severity.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.70" spread="0.381"/>
                    <measurement group_id="O2" value="-4.05" spread="0.378"/>
                    <measurement group_id="O3" value="-4.72" spread="0.378"/>
                    <measurement group_id="O4" value="-4.05" spread="0.385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SPARC Placebo</title>
          <description>SPARC Placebo administration</description>
        </group>
        <group group_id="E2">
          <title>SPARC1310 I</title>
          <description>SPARC1310 I administration</description>
        </group>
        <group group_id="E3">
          <title>SPARC1310 II</title>
          <description>SPARC1310 II administration</description>
        </group>
        <group group_id="E4">
          <title>SPARC1310 III</title>
          <description>SPARC1310 III administration</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood cortisol decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shravanti Bhowmik, MD</name_or_title>
      <organization>SPARC</organization>
      <email>shravanti.bhowmik@sparcmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

